 This study will evaluate the efficacy and safety of oral capecitabine Xeloda versus 5-fluorouracil 5-FU, in combination with intravenous IV cisplatin, in participants with advanced andor metastatic gastric cancer. The anticipated time on study treatment is at least 6 weeks and continued up to disease progression, and the target sample size is 300 individuals. 